| Drug Type Trispecific T-cell engager (TriTE) | 
| Synonyms SO | 
| Target | 
| Action stimulants, modulators | 
| Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HER2 modulators(Receptor tyrosine-protein kinase erbB-2 modulators), VEGFR2 modulators(Vascular endothelial growth factor receptor 2 modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | China  | - | |
| Neoplasms | Preclinical | China  | - | 






